logo
Plus   Neg
Share
Email

Genentech's Late-stage Study On Pemphigus Vulgaris Meets Primary Endpoint

Genentech, a member of the Roche Group (RHHBY), reported that late-stage PEMPHIX study showed its Rituxan or rituximab superior to Mycophenolate Mofetil in patients with pemphigus vulgaris.

The study met the primary endpoint at week 52, with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the mycophenolate mofetil arm. All secondary endpoints were statistically significant in favor of Rituxan.

"The PEMPHIX study showed that 40% of people in the study could achieve complete remission from painful blistering without the need for corticosteroids for 16 weeks or more and that Rituxan may be a superior treatment option to mycophenolate mofetil," said Levi Garraway, chief medical officer and head of Global Product Development.

Pemphigus vulgaris is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. Mycophenolate Mofetilis an unapproved, commonly used treatment for Pemphigus vulgaris that is recommended in published treatment guidelines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved the first contact lens developed for slowing the progression of myopia or nearsightedness in children between the ages 8 and 12 years at the initiation of treatment. This could also help in ultimately reducing risk of developing other eye problems. The regulator granted approval for CooperVision Inc.'s MiSight contact lens. Amazon plans to more than double its corporate workforce in Las Vegas by creating 125 additional jobs in the city. The e-commerce giant recently opened a new 30,000 square foot office in Town Square in downtown Las Vegas and plans to expand its corporate workforce in the area to support its Human Resources division. Amazon also said it will donate $100,000 to two food bank partners. Consumer Reports has once again recommended Tesla's Model 3 and Model S sedans as reliable, after the vehicles were previous downgraded by the organization. Consumer Reports said that the two sedans regained its recommendation due to improved reliability reports from owners of the cars, based on the results of its annual Auto Reliability Survey that were announced Thursday.
Follow RTT
>